Amal Therapeutics
SwitzerlandWho owns Amal Therapeutics?
Amal Therapeutics is a Swiss Biotech company, now owned by Boehringer Ingelheim, which acquired it in 2019 from High-Tech Gruenderfonds (HTGF) and Boehringer Ingelheim Venture Fund.
Hand-verified · updated 2026-07-07
Open JSON · CC-BY
Key facts
- ·Fully exited in 2019 to Boehringer Ingelheim.
- ·Average hold across 2 realized cycles: 4 years.
Ownership history
2 ownership periods · co-invest detected
High-Tech Gruenderfonds (HTGF) sold Amal Therapeutics to Boehringer Ingelheim in 2019 after 5 years.
Boehringer Ingelheim Venture Fund sold Amal Therapeutics to Boehringer Ingelheim in 2019 after 3 years.
More from HTGF II
Other portfolio companies in the same fund.
Germany
More PE-backed in Biotech
Comparable biotech deals from other GPs.
USQuestions
Who owns Amal Therapeutics?
Amal Therapeutics is now owned by Boehringer Ingelheim, which acquired it in 2019 from High-Tech Gruenderfonds (HTGF) and Boehringer Ingelheim Venture Fund.
When did Boehringer Ingelheim acquire Amal Therapeutics?
Boehringer Ingelheim acquired Amal Therapeutics in 2019, buying from High-Tech Gruenderfonds (HTGF) and Boehringer Ingelheim Venture Fund.
Who did Amal Therapeutics sell to?
High-Tech Gruenderfonds (HTGF) and Boehringer Ingelheim Venture Fund sold Amal Therapeutics to Boehringer Ingelheim in 2019 (Trade Sale).
Who has owned Amal Therapeutics over time?
Amal Therapeutics has been through 2 private-equity ownership periods: High-Tech Gruenderfonds (HTGF) · via HTGF II · 2014–2019 · sold to Boehringer Ingelheim · (Trade Sale); Boehringer Ingelheim Venture Fund · via Boehringer Ingelheim Venture Fund · 2016–2019 · sold to Boehringer Ingelheim · (Trade Sale).